Rationale, aims and objective: Cross-country comparisons of cystic fibrosis (CF) outcomes can potentially identify variation in care but are dependent on data quality.
been formally tested.
We investigated this issue by using prospective Sheffield Adult CF Centre encounter-based FEV 1 data to establish whether annual review FEV 1 were always collected during periods of clinical stability.
We then went on to repeat our analysis using data from the UK CF registry to determine if the Sheffield findings also apply UK-wide.
| METHODS AND MATERIALS
Encounter-based FEV 1 data were prospectively collected in the Sheffield Adult CF centre between 1 January and 31 December 2016 from every adult who contributed data to the UK CF registry, excluding those who had lung transplantation (n = 7) or on ivacaftor (n = 13).
Annual reviews were performed according to usual practice. In addition, clinicians' opinion of health status and Fuchs' criteria 10 were recorded during every encounter involving clinician review, including outpatient clinics, ward reviews, and home visits. FEV 1 readings were deemed to be taken in a period of clinical stability if there was no exacerbation, no requirement for intravenous antibiotics, and ≤3
Fuchs' symptoms present. Every annual review FEV 1 was matched to another clinically stable FEV 1 that was closest to the annual review.
Mean paired difference and paired t test P-value were calculated.
Non-parametric comparisons were also performed to check the robustness of the results.
The UK registry has no "stable FEV 1 " data but collects best FEV 1 data since 2012 for the European registry. 11 We therefore quantified the group-level discrepancy between best FEV 1 and annual review People who had lung transplantation (n = 330) or on ivacaftor (has transformative effect on lung health but unavailable commercially in 2010, 12 n = 281) in the UK registry were excluded. People attending the adult Sheffield CF centre were also excluded to avoid duplicate analysis of the same cohort.
All analyses were performed by using SPSS v22 (IBM Corp, Armonk, NY, USA 
| RESULTS
A total of 174 adults were included for Sheffield analysis and 2995 adults for the UK CF registry analysis. Adults with and without best FEV 1 data in the UK CF registry shared similar clinical characteristics (see Table 1 ). Table 2 ). For all annual reviews performed during periods of clinically instability, the group-level discrepancy was larger at −8.0%
(95% CI −11.2% to −4.9%). In Sheffield, whereby 20% of the clinician reviewed annual reviews were performed during periods of clinical instability, the overall group-level discrepancy between best and annual review FEV 1 was −6.1% (95% CI −7.5 to −5.1%).
A similar overall group-level discrepancy of −5.6% (95% CI −5.9%
to −5.4%) was observed in the UK registry, suggesting that the proportion of annual reviews performed during periods of clinical instability around the UK was similar to Sheffield. This discrepancy was larger among younger adults, similar to the pattern of FEV 1 discrepancy observed in the US-UK comparison. 7 Similar results were obtained with non-parametric comparisons (see Table 3 ), suggesting that our estimates are robust. 13 Our analysis was restricted among adults due to data availability in Sheffield. Although most of the US-UK FEV 1 differences were among younger people, the lack of differences among older adults does not exclude the possibility that lung health at a group level in the United Kingdom was being under-estimated.
| DISCUSSION
Our analysis cannot conclusively prove that the US-UK FEV 1 comparison was biased because some "clinically unstable" FEV 1 in the United States may be mislabelled as "clinically stable." However, we speculate that under-estimation of lung health may be more of a problem with the UK data entry system, which does not have encoun-
ter-based FEV 1 data. Data are typically only entered once annually in the UK with a mid-January deadline to complete data entry for preceding year, yet annual reviews are staggered throughout the year due to capacity issues. Around 40% of annual reviews are performed during the final quarter of the year, 7 when exacerbation risks are higher. 14 nutritional outcomes), which is not surprising given that Australian children were much more likely to be diagnosed after newborn screening (65.8%) compared with US children (7.2%). 5 Australia also delivered more aggressive treatment for pulmonary exacerbations, 5 which contributes to better lung health. [16] [17] [18] Despite the very strong correlation between nutritional outcomes and lung health, 19-21 FEV 1 were actually similar between Australian and US children. 5 In fact,
Australian children had significantly lower FEV 1 after adjusting for the mode of diagnosis. 5 In 2003, the US registry started collecting encounter-based FEV 1 data whilst the Australian registry was collecting FEV 1 data annually. 5 It may be that annual FEV 1 in Australia was under-estimating the lung health of Australian children, which could explain the disconnect between nutritional outcomes and lung health observed in the US-Australia comparison.
Differences in outcomes detected by registry comparisons attract significant attention; hence, a rigorous process should be adopted to Systematic data differences should be considered when analysing data and interpreting results from cross-country registry comparisons.
We have demonstrated that UK annual reviews are not always collected during periods of clinical stability. This has potential impact on comparisons with the US registry that collects encounter-based FEV 1 .
